Invasive Mold Infections in Chronic Granulomatous Disease: A 25-Year Retrospective Survey
Open Access
- 15 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (12), e159-e169
- https://doi.org/10.1093/cid/cir731
Abstract
Background. Invasive fungal infection (IFI) represents a life-threatening condition for patients with chronic granulomatous disease (CGD) and causes one-third of deaths in this population. This study offers a descriptive review of invasive mold infection (mIFI) in children with CGD over an extended period of time. Methods. In a cohort of patients with CGD registered in the French National database for Primary Immunodeficiency, we performed a retrospective review of proven mIFI episodes (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group 2008 criteria) occurring from 1984 through 2009. Results. Twenty-nine proven mIFIs were identified in 24 patients. Thirteen (54%) of 24 children were receiving itraconazole prophylaxis. Seven episodes were caused by Aspergillus fumigatus, 10 by Aspergillus nidulans, 2 by Aspergillus species, and 6 by other opportunistic molds (4 patients only had positive pathological examination findings). First proven mIFI occurred later in the group that received itraconazole than in the group without (median time to mIFI, 10 vs 4 years; P < .01), with a higher proportion of infections due to A. nidulans and other opportunistic molds (P < .05). Course of IFI was complex, with the median duration of therapy and hospitalization reaching 446 and 153 days, respectively. Combined antifungal therapy was commonly used. Four patients received geno-identical hematopoietic stem cell transplantation as salvage therapy. Global cure rate among the cohort reached 75%, but sequelae were frequent. Prognosis has improved over time (43% mortality during 1985–1990 vs 6% thereafter; P = .06). Mortality tended to be lower in the group that recieved itraconazole prophylaxis but at the cost of a longer duration of therapy among cured patients. Conclusions. Management of mIFI remains challenging in patients with CGD, but significant improvements have been made over the past decade.Keywords
This publication has 45 references indexed in Scilit:
- Residual NADPH Oxidase and Survival in Chronic Granulomatous DiseaseNew England Journal of Medicine, 2010
- Chronic Granulomatous Disease: The European ExperiencePLOS ONE, 2009
- Chronic granulomatous disease in Israel: Clinical, functional and molecular studies of 38 patientsClinical Immunology, 2008
- Special Article: Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registryClinical and Experimental Immunology, 2008
- Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in JapanEuropean Journal of Pediatrics, 2008
- Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: An Italian multicenter studyClinical Immunology, 2008
- Chronic granulomatous diseaseCurrent Opinion in Immunology, 2003
- Long-term follow-up and outcome of 39 patients with chronic granulomatous diseaseThe Journal of Pediatrics, 2000
- Follow up of patients with chronic granulomatous disease diagnosed since 1990Clinical and Experimental Immunology, 2000
- Chronic Familial GranulomatosisAmerican Journal of Diseases of Children, 1967